Remibrutinib Label Expansion and Exosome Advances Headline Dermatology Times Coverage
Dermatology Times flags a remibrutinib label expansion and exosome progress, but the syndicated text names no trials, indications, or dates. Here is what holds up.
Topic
Label Expansion
Topic
Label Expansion
J&J Pharma Chief Eyes Icotyde Cross-Indication Expansion
Johnson & Johnson's incoming pharmaceutical chief told Fierce Pharma the company expects Icotyde's psoriasis launch momentum to r…